By Fineline Cube 
China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004 has been accepted for review by the National Medical Products Administration (NMPA). Previously granted priority review status, this next-generation anti-drug resistance TRK inhibitor is anticipated to offer a novel therapeutic option for patients suffering from advanced solid tumors.
Indication and Usage
VC004, a Category 1 small molecule targeted anti-tumor drug, is indicated for the treatment of adult and adolescent patients aged 12 and above with solid tumors harbouring the neurotrophin tyrosine receptor kinase (NTRK) fusion gene. This includes patients with locally advanced, metastatic disease, or scenarios where surgical resection may lead to severe complications. It also targets those with no satisfactory alternative treatments or prior treatment failures.-Fineline Info & Tech